Deferoxamine in the management of COVID-19 adult patients admitted to ICU: a prospective observational cohort study
Description
CONCLUSIONS: Deferoxamine may have mortality and clinical improvement benefits in COVID-19 adults admitted to ICU. Further powered and controlled studies are required.